Development and Dissemination of a Preconception Health Care Tool in Primary Care

Rebekah Barrett¹, Lena Salach², Amanda van Hal², Lindsay Bevan², Deanna Telner³ 1. Regent Park Community Health Centre, Toronto, ON, 2. Centre for Effective Practice, Toronto, ON, 3. South East Toronto Family Health Team, Toronto, ON

Context & Objective

Good health begins even before conception. Recommendations from Ontario's No Time to Wait: The Healthy Kids Strategyⁱ suggest that optimizing patients' health before conceiving will improve their child's chances of enjoying good health throughout their lives. In response to these recommendations, the Ontario Ministry of Health and Long-Term Care engaged the Centre for Effective Practice (CEP) to develop and disseminate the Preconception Health Care Tool. The tool is designed to improve maternal and infant health outcomes in primary care by guiding providers' discussions of health promotion and illness prevention strategies with all patients of reproductive age.

Design

The tool was developed using CEP's tool development process.

- A working group comprised of a primary care nurse practitioner, a family physician, and CEP staff conducted a comprehensive search, review, and appraisal of existing clinical evidence. Through this process the working group integrated all available evidence and resources into one tool.
- The tool was tested and refined based on feedback from individuals and organizations with expertise in maternal and infant care, and providers who practice comprehensive family medicine.
- By engaging target end-users and key stakeholders throughout the tool development process, CEP was able to better understand the individual needs and challenges faced by providers delivering preconception care, as well as gain insight on how to best address those needs and challenges in the tool.

Get Involved

CEP engages providers and stakeholders as often as possible in our tool development processes and related projects. If you would like to:

- Provide feedback on clinical tools
- Receive our newsletter
- Participate in Working Groups
- Learn more about our organization

Please visit www.effectivepractice.org and join the conversation.



Tool Highl Some key aspec

- It is available
- It contains li
- focus on Car
- The content

Contact Information Lindsay Bevan, Project Coordinator Centre for Effective Practice **T** 647-260-7880 **E** lindsay.bevan@effectivepractice.org

Figure 1. Tool Development Process

o confirmed	Draft Content Development	T re		n Care Tool will help to vide guidance and reso		roviders' approach to precor 1 patients. CEP is currently v			
grey literature search:Environmental scan:lications and relevantRelevant programs, organizations, and information identifiedorts identifiedand information identifieded and categorized according to clinical category and aspects of care		Figure 2. Preconception Health Care Tool							
			Centre for Effective Practice			Prevent & Promote	Screen	Manage	
ent developed			Patient Name:	Preconception Health Care involves identifying potential phy risk factors for adverse pregnancy outcomes, and reducing the and intervention. Preconception Health Care focuses on healt reproductive age. It is an important opportunity for primary ca the critical period for fetal development often occurs before p below should be addressed with every individual of repro	ose risks prior to conception through counselling, education, h promotion and illness prevention for everyone of are providers to improve maternal and infant outcomes, as renatal care begins. Each of the preconception topics	 Immunizations: All individuals of reproductive age shout Vaccinate: Varicella HPV Tetanus, Measle Rubella Influenza Diphtheria, Mump Hepatitis B Influenza Og Infectious Diseases: Prevention and screening of the 	As, s S S S S S S S S S S S S S S S S S S	Provide all immunizations required prior to conception with the exception of the flu vaccine, which can be administered before and/or during pregnancy.	
			Birth Date: dd/mm/yy	If you are interested in providing feedback on this to References and additional resources available at ww	ool, please visit www.effectivepractice.org/feedback. /w.eff ectivepractice.org/preconception	□ HIV □ Hepatitis B □ Tuberculosis □ Toxoplasmo □ Parvovirus □ Hepatitis C □ Cytomegalovirus	Screen: HIV Screen if High Risk: Hepatitis C Tuberculosis	 Inform women who screen positive for HIV, Hepatitis B or C of risk for vertical transmission, and offer appropriate treatment²⁰. Treat women with Tuberculosis prior to conception²⁰. 	
ent circulated to: nd organizations with an interest and naternal and infant care o practice comprehensive family medicine	Stakeholder and Target End-User Input		 No → Discuss contraception options. Not sure → <u>Choosing Wisely Tool².</u> Inform women of reproductive age that natural fertility and assisted reproductive technology success is significantly lower for women in their late 30-40s.³ Reproductive History: A detailed reproductive history success is significantly success is success i		If positive pregnancy test, discuss options for prenatal care and refer accordingly.	 10 Family and Genetic History: Obtain 3 generation family history to identify²¹ ♥ ➡: Congenital malformations, □ Consanguinity (first cousins or closer). Developmental delays, learning disabilities. □ Ethnicity □ Genetic disorders²². ♥ ➡ □ Family history of a genetic condition. □ History of infertility, multiple microariagor (>2 or all male fature) 	 Tay-Sachs in French Canadian individuals if family history preser Hematopoietic stem cells screening (Ashkenazi Jewish Screenin 		
oack collected, vised			Gravida (G): Abortions (A): Full-Term (T): Living Children (L): Premature (P): Details: 03 Sexual Health:	Preterm Birth Stillbirth Gestational DM Reclampsia Miscarriage Caesarean Birth	 Provide appropriate referrals. Advise women with prior caesarean delivery to wait at least 18 months prior to conception. Recommend folic acid 5mg daily prior to conception and for 12 weeks after conception if positive history of neural tube defect. Recommend >18 and <59 month interpregnancy interval (IPI). 	 miscarriages (>3 or all male fetu 11 Nutrition: Eat well with <u>Canada's Food Guide²⁴</u>. Recommend folic acid 0.4-1.0mg daily <u>(through a multivitation or supplement)</u>¹⁵ and folate rich diet, prior to conception and throughout pregnancy. Recommend <u>calcium 1000mg daily</u>²⁵ through food and/or supplement Recommend essential fatty acid rich diet, including omega 3 and 	 min on Screen for issues regarding access to food, nutrition, storage, cooking facilities and folic acid. Screen for iron deficiency anemia if at risk. 	□ Provide referral to Dietitian or appropriate community agencies.	
roviders from a variety of practice settings engaged through: testing nterviews			All individuals should be counseled about safer sexual practice. Chronic Medical Conditions: Optimize management for <u>Motherisk</u> ⁶ * • * should be consulted for the safety of any medications taken by patients with chronic conditions. Motherisk Helpline: 1-877-439-2744	Gonorrhea Genital Herpes (if lesions) r the following diseases, as suboptimal control or treatments can increas long-standing hypertension. Alternatives to ACE-Is are recommended in women of reproductive age. Avoid estrogen-containing contraception options for women with severe hypertension.	Systemic Lupus Erythematosus, Rheumatoid Arthritis, and other Autoimmune Diseases: Delay conception until good control is achieved. Discuss natural history of disease during/after	 □ <u>Recommend avoiding raw/undercooked meat and fish and unpasteurized milk and cheese²⁶. ↓ ↑</u> □ <u>Caffeine <300mg/day²⁷. ↓ ↑</u> □ Recommend <u>vitamin D 600 IU (15 µg) supplementation daily²⁸. ↓ 1</u> □ Recommend 2.6 micograms of vitamin B12 daily through supplement or multivitamin. 	• •		
back collected, vised			 Asthma: Delay conception until good control is achieved. Cancer: All individuals with cancer should be counseled regarding the potential effects of treatment on fertility and informed of options to preserve fertility, if desired, and referred appropriately. Diabetes: Increased risk of birth defects can be mitigated with good preconception glycemic control. Encourage contraception for those without good control. Folic acid 5mg daily prior to conception and for 12 weeks after conception. ACE-Is and statins are contraindicated. Estrogen-containing contraception options should be avoided for those with DM >20 years or target end-organ damage. HIV: Transmission risk to fetus is ~2% with antiretroviral therapy. Efavirenz is contraindicated. Antiretroviral drugs may interfere with 	Renal Disease: Encourage optimal control prior to conception, including normal BP. Use alternative to ACE-Is. Consult with specialist.	 pregnancy. Cyclophosphamide, Methotrexate, and Leflunomide are contraindicated. Avoid estrogen-containing contraception options in women with SLE and positive/unknown antiphospholipid antibody. Discuss use of aspirin and heparin with rheumatologist for women with SLE and antiphospholipid antibody syndrome. Thromboembolic Disease: Counsel women that risk for VTE during pregnancy and postpartum is increased, and many will require anticoagulation treatment. Coumadin is contraindicated. Avoid estrogen-containing contraceptive options. Thyroid Disease: Achieve euthyroid state prior to conception. Women with hypothyroidism should increase their dose of levothyroxine by 30% as soon as pregnancy occurs. Radioactive 	12 Weight Status: Weight can increase risk of adverse pregTarget Body Mass Index (BMI) = 18.5-24.9 (for ages ≥19)Waist Circumference (WC) ²⁹ ♥ Male TargetWaist Circumference (WC) ²⁹ ♥ Male TargetEuropean, African, Eastern Mediterranean, Middle Eastern<102cm	□ Screen <u>BMI³¹ <mark>⇔</mark> </u> annually. BMI = weight(kg)/height(m)2	 Underweight (BMI <18.5) Overweight (BMI = 25-29.9) Obese (BMI >30) Provide appropriate referrals for management. Recommend folic acid 5mg daily prior to conception and for 12 weeks after conception for obese individuals. Discuss recommended healthy weight gain³² during pregnancy and recommend contacting EatRight Ontario 1-877-510-5102. 	
n, review, proof, sion, approval	Production and Distribution		hormonal contraceptive methods. Refer to specialist. Hypertension: Increased risk for adverse fetal and maternal outcomes. Assess for target-end organ damage in those with	medication recommended, when possible. Valproic acid, lithium, and topiramate are contraindicated. Many antiepileptic medications may interfere with hormonal contraceptive methods.	iodine is contraindicated. Screen all women for CBC and TSH, prior to conception.	 Recommend at leaded and the second sec	 Physical Activity: Being physically active prepares the body for the physical demands of pregnancy, and can assist with stress management. Recommend at least 150 minutes of moderate to vigorous aerobic physical activity per week, in episodes of 10 minutes or more. Add muscle and bone strengthening activities at least 2 days per week. See the <u>Canadian Physical Activity Guidelines</u>³³. Psychosocial Stressors: Stress can have negative affects on pregnancy outcomes. 		
of final tool	Diotribution		Human teratogenicity risk is unknown for the majority of medica- tions. Use caution when prescribing for women of reproductive age. Consult <u>Motherisk</u> ⁶ . *	 Screen for teratogenic medication use: Prescribed Medications Over-the-Counter Medications Complementary and Alternative Therapy (herbal, natural, weight loss, athletic products or supplements, etc.) 	 Potentially teratogenic medications should be changed to safer options. Women should be counseled not to stop prescribed medications without consulting with their provider. Recommend folic acid 5mg daily prior to conception and for 12 weeks after conception for women taking folate antagonists (ex. methotrexate, sulfonamides, and antiepileptics). 	Identify stressors and discuss strategies to reduce impact.	Screen: □ Access to Care □ Housing □ Social Isolation (newcomers, language barriers) ³⁴ □ Intimate Partner □ Social Support □ Unemployment □ Workplace Stress □ Unhealthy Relationsh	 Inform women that violence often worsens during pregnancy and discuss safety plan. Provide <u>appropriate referrals</u>³⁶. * ² 	
ights			 Promote mental health wellness through adequate sleep, work-life balance, stress reduction and social connectedness. Tobacco Use: 	Screen: □ <u>Depression</u> [®] □ Screen for family history of mental □ <u>Anxiety</u> [®] □ □ <u>Other</u> ¹⁰ □ □ <u>Depression</u> [®]	 Bipolar Disorder Mood Disorder Schizophrenia Counsel women with mental health diagnoses of risks of pregnancy and relapse. Strategize management. Stabilize/optimize mood and anxiety level; discuss risks and benefits of medications. 	 In the provided and the pro	sh Solvents (ask about use) Plastics Metals (lead, mercury) Pesticides Teratogenic and/or Gonadotoxic Treatments (chemotherapy, radiation therapy)	 Health Canada's blood methylmercury guidance level in pregnancy or reproductive age: <8mcg/L (40nmol/L). Refer to local health department if potential water/soil exposure. Refer to Occupational Health Specialist as needed. 	
ets of the tool include: e in both paper and web format; nks to current patient and provination sources; and,	vider resources throughou	ıt; with a	Encourage all individuals to be tobacco free prior to conception. 07 Alcohol and Other Substance Use: Encourage all individuals to be substance free prior to conception.	Screen: Tobacco (all forms) Tobacco Exposure (second-hand smoke) Screen: Alcohol Other Substances	 Provide brief intervention and provide <u>appropriate referrals</u>¹¹. Inform women of available <u>patient resources</u>¹² Inform women of available <u>patient resources</u>¹² and Smokers' Helpline 1-877-513-5333. Consult <u>Canadian Smoking Cessation Guidelines</u>¹³. Counsel women with tobacco addictions of risks of pregnancy and relapse. Strategize management. Recommend 35mg of vitamin C daily for smokers. 	FCFP as the Clinical Leads. In addition, the Tool was subject to ex Canada and does not constitute medical or other profession Ontario, the Centre, OCFP, the contributors to this Tool nor any of services through this Tool; (ii) to the extent permitted by appli- entity, including for any loss, damage or injury (including de	Pollutants Gases Radiation Radiation	"), with Rebekah Barrett, MN, NP-PHC and Deanna Telner, MD, MEd, CFPC, Tool was developed as a guide only for primary care providers in cise their own clinical judgment in using this Tool. Neither the Government of , members or volunteers: (i) are providing medical, diagnostic or treatment any individual (including, but not limited to, primary care providers) or	
will be kept up-to-date on an c	mgoing basis.		November 2015		 with addictions¹⁵.♥[↑] Inform women of available patient resources¹⁶♥[↑] and Drug and Alcohol Helpline 1-800-565-8603. Consult low risk drinking guidelines¹⁷.♥[↑] Page 1 of 2 	Centre for Effective Practice November 2015	Ontario College of Family Physicians	 indicates Canadian resources indicates provider resources indicates patient resources Page 2 of 2	

www.effectivepractice.org/preconception



Results

The tool presents information for providers to use over a series of visits with their female and male patients of reproductive age to: • Encourage patients to develop a reproductive life plan;

• Assess and optimize patients' preconception physical and mental health;

• Optimize chronic medical conditions prior to conception;

• Choose safe medications for women who may become pregnant; and,

• Counsel on lifestyle habits (nutrition, physical activity, alcohol, tobacco and other substances). Preliminary data on dissemination has been collected and analyzed. Since the launch of the tool in March of 2015, 1,200 hard copies have been disseminated, and there have been 11,500 visits to the tool web page.

Centre for Effective Practice

i. Ontarios Healthy Kids Panel. (2013). No Time to Wait: The Healthy Kids Strategy.

